ERBB2 and breast cancer: A pilot study that explored the association between gut microbiome and BC risk factors, including receptor status, stage, and grade of BC, showed that women with Her2+ BC had 12–23% lower alpha diversity, higher abundance of Bacteroidetes and lower abundance of Firmicutes compared to Her2- patients [69].